INmune Bio price target raised to $23 from $22 at Scotiabank

Scotiabank raised the firm’s price target on INmune Bio (INMB) to $23 from $22 and keeps an Outperform rating on the shares. The company’s management appears confident a Biologics License Application that will be filed with the FDA around the end of the year will be received positively, the analyst tells investors. Additionally, the firm believes a positive outcome of the XPRo Phase 2 trial is expected to read out in June, which would “completely dwarf” the CORDStrom commercial opportunity.